Free tool · No account
Clinical trials for breast cancer
Breast cancer trials are usually organized around the tumor's subtype: hormone-receptor status and HER2. Trials differ a great deal between early-stage and metastatic disease, so the stage matters when you read eligibility.
2,359 recruiting trials. Showing a sample.
- recruitingNANCT07698314
A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.
Listed by the study for Breast Cancer. Record updated 2026-09-30.
Sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)Full details on ClinicalTrials.gov → - recruitingPhase 2NCT07283692
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Listed by the study for Triple Negative Breast Cancer. Record updated 2026-05-13.
Sponsored by RenJi HospitalFull details on ClinicalTrials.gov → - recruitingNANCT05874492
Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer
FIBROTHERME is a comparative, controlled, randomized, multicenter and simple blinded (investigator) trial. The aim of this study is to evaluate the medical benefit in terms of quality of life on the dermatological sequelae of fibrosis 6 months after a dermatologically oriente...
Listed by the study for Breast Cancer. Record updated 2026-04-13.
Sponsored by Association Francaise pour la Recherche ThermaleFull details on ClinicalTrials.gov → - recruitingNCT04874064
TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence
Triple negative breast cancer (TNBC) is the most aggressive of breast cancers and it is usually treated with chemotherapy even before surgery. In many cases, the chemotherapy completely "melts" the tumor and these patients do well. When the tumor is not eliminated by the chemo...
Listed by the study for Breast Cancer. Record updated 2025-11-28.
Sponsored by Jewish General HospitalFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06793332
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
This study is a single-center, prospective, single-arm clinical trial, which intends to enroll patients with triple-negative breast cancer with brain metastases to receive ivonescimab combined with TROP2 ADC (such as sacituzumab govitecan) treatment until disease progression, ...
Listed by the study for Triple-Negative Breast Cancer (TNBC). Record updated 2025-01-27.
Sponsored by Fudan UniversityFull details on ClinicalTrials.gov → - recruitingPhase 1NCT06910657
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cel...
Listed by the study for Breast Cancer. Record updated 2026-08-05.
Sponsored by ViroMissile, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT06026657
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
This phase Ib/II trial tests the safety, best dose and how well gemcitabine and ex vivo expanded allogenic universal donor TGFBi NK cells with or without naxitamab work for the treatment of patients with GD2 expressing, HER2 negative breast cancer that has spread from where it...
Listed by the study for Anatomic Stage IV Breast Cancer AJCC v8. Record updated 2026-07-23.
Sponsored by Margaret Gatti-MaysFull details on ClinicalTrials.gov → - recruitingNANCT07776301
Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast Cancer
This study aims to evaluate and report the clinical adverse events and dosimetric parameters in breast cancer patients undergoing an "all-in-one (AIO)" one-stop, fully automated radiotherapy workflow. By systematically tracking these clinical and physical metrics, we seek to e...
Listed by the study for Breast Cancer. Record updated 2026-08-20.
Sponsored by Fudan UniversityFull details on ClinicalTrials.gov → - recruitingPhase 3NCT06790693
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-muta...
Listed by the study for Breast Cancer. Record updated 2026-10-06.
Sponsored by Hoffmann-La RocheFull details on ClinicalTrials.gov → - recruitingNANCT06856200
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
This study adopts a single-center, open-label, non-randomized trial design. It plans to enroll patients with HR- positive, HER2- negative advanced breast cancer who are resistant to (neo)adjuvant endocrine therapy. Dose-escalation and dose-expansion studies will be carried out...
Listed by the study for Advanced HR - Positive, HER2 - Negative Breast Cancer. Record updated 2025-03-04.
Sponsored by Fudan UniversityFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-10-12. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this breast cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.